CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Report for D000505: Alopecia NIH

(Synonyms: Alopecia)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (8)

Name (Synonyms) Correlation
drug351 Biological sampling Wiki 0.71
drug352 Biological test Wiki 0.71
drug1935 Proxalutamide Wiki 0.71
drug799 Dutasteride Wiki 0.71
drug420 CAG length <22 Wiki 0.71
drug421 CAG length >=22 Wiki 0.71
drug1270 Ivermectin Wiki 0.17
drug262 Azithromycin Wiki 0.12

Correlated MeSH Terms (4)

Name (Synonyms) Correlation
D011470 Prostatic Hyperplasia NIH 0.71
D006965 Hyperplasia NIH 0.71
D045169 Severe Acute Respiratory Syndrome NIH 0.04
D018352 Coronavirus Infections NIH 0.03

Correlated HPO Terms (2)

Name (Synonyms) Correlation
HP:0002293 Alopecia of scalp HPO 1.00
HP:0008711 Benign prostatic hyperplasia HPO 0.71

There are 2 clinical trials

Clinical Trials

1 In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity

The COVID-19 Androgen Sensitivity Test is a non-invasive In-Vitro Diagnostic device that utilizes Next Generation Sequencing Technology (NGS). The results of the test are used by a physician to assess the risk of developing severe symptoms following COVID-19 infection, The COVID-19 Androgen Sensitivity Test requires a health care professional to collect a DNA sample using an FDA cleared DNA sample collection kit.

NCT04368897 SARS-CoV 2 COVID COVID-19 Androgenetic Alopecia Androgen Receptor Abnormal Androgen Deficiency Diagnostic Test: CAG length <22 Diagnostic Test: CAG length >=22
MeSH:Alopecia
HPO:Alopecia Alopecia of scalp Frontal balding

Primary Outcomes

Description: Defined as 28 days minus the number of days from randomization to discharge home. If a patient has not been discharged home prior to day 28 or dies prior to day 28, hospital free days will be zero.

Measure: Hospital-free days to Day 28 [ Time Frame: 28 days]

Time: 28 days

Description: Defined as discharged, hospitalization, admission to intensive care unit [ICU] and death

Measure: 1. Severity of Disease

Time: Day 28

2 Anti-Androgen Treatment for COVID-19

This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection

NCT04446429 COVID-19 SARS-CoV2 Androgenetic Alopecia Prostate Cancer Benign Prostatic Hyperplasia SARS (Severe Acute Respiratory Syndrome) Drug: Dutasteride Drug: Ivermectin Drug: Azithromycin Drug: Proxalutamide
MeSH:Severe Acute Respiratory Syndrome Coronavirus Infections Prostatic Hyperplasia Alopecia Hyperplasia
HPO:Alopecia Alopecia of scalp Benign prostatic hyperplasia Frontal balding

Primary Outcomes

Description: Percentage of subjects hospitalized due to COVID-19

Measure: COVID-19 hospitalization

Time: 30 days

Description: COVID Ordinal Scale defined as: Death Hospitalized on invasive mechanical ventilation or ECMO ( extracorporeal membrane oxygenation) Hospitalized on non-invasive ventilation or high flow nasal cannula Hospitalized on supplemental oxygen Hospitalized not on supplemental oxygen Not hospitalized with limitation in activity (continued symptoms) Not hospitalized without limitation in activity (no symptoms)

Measure: COVID-19 Ordinal Outcomes Scale

Time: 30 days

Secondary Outcomes

Description: Symptoms severity of COVID-19 using Brescia-COVID Respiratory Severity Scale (BCRSS)/Algorithm

Measure: Symptoms severity of COVID-19

Time: 30 days

HPO Nodes

HP:0002293: Alopecia of scalp
Genes 29
COL17A1 PLEC ITGB4 ERCC3 KLHL24 TARS1 MPLKIP TTC7A RHOA COL17A1 MMP1 CLDN1 TP63 COL3A1 LAMA3 LAMB3 LAMC2 EBP SLC39A4 MBTPS2 ERCC2 GJB2 ECM1 COL7A1 GTF2E2 ITGB4 GTF2H5 RNF113A KRT14
Protein Mutations 0
SNP 1
rs2180439
HP:0002292: Frontal balding
Genes 4
NR3C1 DMPK WNT4 CNBP
Protein Mutations 0
SNP 0
HP:0001596: Alopecia
Genes 287
PLEC APCDD1 KLHL24 EDARADD MPLKIP RAG1 FGFR1 ARHGAP31 NOP10 TERT KRT81 LSS TP63 LAMA3 PNPLA6 ERCC5 PADI3 ALMS1 HR KRAS SLC39A4 MBTPS2 FLI1 PORCN LAMA3 RAG2 PKP1 GTF2H5 WRAP53 SLC29A3 DMXL2 FZD2 HLCS GNA11 DSG4 LMNA ATR HFE ARHGAP31 KRT81 UROS TTC7A NSDHL XPC RHOA DSP SMARCA2 AEBP1 MBTPS2 LSS GJB6 HRAS ROR2 LMNA ABCD1 EPS8L3 RIPK4 GTF2E2 GJA1 RNF113A RPL21 ZNF341 KDM5C NXN MGP PLEC VDR CD28 LIG4 SNRPE EDNRA DOCK6 IL7R GJB2 FTL COL7A1 IKBKG CLDN1 HTRA1 CERS3 TINF2 COL3A1 DSG4 NRAS ALOXE3 SOX18 NRAS MBTPS2 MBTPS2 DLL4 NFKB2 NFKB2 IKBKG RIPK4 SLC39A4 FGFR1 KRT14 PEX7 ADA KRAS AHSG COL17A1 PTPN22 LAMB3 UROD RBPJ GJB6 ABHD5 RTEL1 HLA-DRA GJB6 ABHD5 KRT86 OFD1 CTLA4 HFE MMP1 SPP1 DCAF17 EXOSC2 DCAF17 DSP UBR1 TINF2 EBP DCLRE1C TP63 MBTPS2 FAM111B KRT85 PORCN ALOXE3 TGM1 SLITRK1 HR CSTB HLCS ACVR1 SASH1 KRT16 COL17A1 TP63 XPA ERCC3 LIPH RAG2 ZMPSTE24 ALOX12B HFE OFD1 LAMC2 DSP DVL1 LMNA FOXN1 LMNA KRT83 RNU4ATAC PNPLA1 ANTXR1 NPM1 STAT4 KRT86 AIRE AIRE RMRP TP63 PRKACA UQCRFS1 HR FOXN1 ERCC3 HRAS ACVR1 VDR JUP TRPV3 NOTCH1 DMPK DKC1 BTD RBM28 SNRPE LAMC2 BCS1L DVL3 BTNL2 NECTIN1 GJB4 EBP COL7A1 TGM1 GJB3 MMP1 ERCC2 LMNA GJB2 ECM1 RBM28 CHD7 IRAK1 ABCA12 TERC NECTIN4 CD28 CASR IL7R KRT17 TERT TARS1 IL2RG ALMS1 BMP2 KRAS NFKB1 COL18A1 DDB2 TINF2 WNT5A TRPV3 ALX4 PARN EOGT FOXP3 KDM5C AHSG WNT10A KDSR RIN2 SOX18 PIK3R1 GJB2 TERC GJA1 ERCC2 DCLRE1C CTLA4 STUB1 AP1B1 ITGB4 IL2RA TGM1 NIPAL4 PERP NHP2 HLA-DRB1 LMNA ALX4 CLDN1 ZMPSTE24 KRT74 EDAR KRT83 BTK USB1 ZMPSTE24 MBTPS2 LAMB3 TGM3 ERCC4 KRT6B ECM1 BTD BCS1L CTC1 LPAR6 MCCC2 ITGB6 KRT6A GJA1 RECQL4 HR EPS8L3 TNFRSF1B COL7A1 DKC1 ANTXR1 WNT10A TP63 RAG1 SLC30A2 ITGB4 COL3A1 TNFRSF1B SOX18 ALOX12B PARN
Protein Mutations 0
SNP 0